Kyle LaHucik reports tirzepatide, sold as Mounjaro and Zepbound, made up 66% of Lilly's revenue in the quarter.
Recap by typeshit. Post by Kyle LaHucik on X.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
That already tops Lilly's full 2025 capital allocation of $32.3 billion, a sign of how much its obesity drug cash is fueling spending.
The Alpha Bioscience Labs owner says US-made, tested peptides can replace gray market supply. FDA staff had advised against adding the six to the bulks list.
Loading…